2026-04-17T03:45:31Zhttps://recercat.cat/oai/request

oai:recercat.cat:10459.1/836682025-12-15T19:12:49Zcom_2072_3622col_2072_479130

Impact of Obstructive Sleep Apnea (OSA) in COVID-19 Survivors, Symptoms Changes Between 4-Months and 1 Year After the COVID-19 Infection Labarca, Gonzalo Henríquez-Beltrán, Mario Lamperti, Liliana Nova Lamperti, Estefania Sanhueza, Sergio Cabrera, Camilo Quiroga, Romina Antilef, Barbara Ormazábal, Valeska Zúñiga, Felipe Castillo, Daniela Horta, Gloria Enos, Daniel Lastra, Jaime González, Jessica Targa, Adriano Barbé Illa, Ferran COVID-19 Cytokines Neurocognitive impairment Obstructive sleep apnea Symptoms Objective: To determine the association between Obstructive Sleep Apnea (OSA) with long-term symptoms and inflammatory cytokines, exploring the changes between 4-months and 1-year after COVID-19 infection. Methods: We conducted an observational, prospective cohort study, including patients ≥18 years old with confirmed diagnosis of COVID-19 between April to July 2020. All participants underwent two clinical follow-up visits, the first at 4-months (Visit 1) and the second at 1 year, after SARS-CoV-2 infection (Visit 2). Plasma glucose, total cholesterol, HDL, and triglycerides. Regarding pulmonary function, spirometry and lung diffusion capacity tests were assessed. For mental and neurocognitive evaluation, a short-form (SF-12), Beck depression and Hospital-Anxiety depression questionnaires were conducted at both time-points, whereas the Montreal Cognitive assessment was conducted during the second follow-up. Regarding to sleep evaluation, Epworth Sleepiness Scale, Insomnia Severity index and STOP-BANG questionnaire were conducted. Additionally, a home sleep apnea test and 7-day wrist actigraphy were performed in all participants. Inflammatory cytokines were measured using an inflammatory cytokine bead array kit. p-values < 0.05 were considered statistically significant and statistical analyses were performed using R software. Results: A total of 60 patients were included in the first follow-up, from which 57 completed the second follow-up. The mean age was 46.4 years-old (SD ± 13.1) and 53.3% were male. 30% of cases reported mild COVID-19 infection, 28.3% with moderate illness, and 41.6% with severe illness. Moreover, 56.6% of them were admitted to the ICU. Regarding to metabolic values, the OSA group showed higher values of insulin resistance (IR) (27%), systolic blood pressure (SBP) 135.2 (±19.1), dyslipidemia (67.5%), total cholesterol 202.1 (±60.5), triglycerides 176.1 (±119.0) and HOMA-IR 9.0 (±18.8) in comparison with the non-OSA group. 1 year after COVID-19 infection, DLCO test remains abnormal in OSA patients (25% OSA vs. 3.6% non-OSA, p = 0.02). Finally, those participants with OSA who develop ARDS reported an adjusted OR 20.4 (95%-CI, 1.04-504) risk of neurocognitive impairment. Discussion: Among patients with previous COVID-19, OSA impact the development of incident glycemic, neurocognitive impairment, and abnormal functional pulmonary changes that persist up to 1 year since acute phase. This study was supported by the Agencia Nacional de Investigación y Desarrollo (ANID, COVID1005), Chilean Government. GL declares funding for research by the American Academy of Sleep Medicine (AASM, 254-FP-21). JG, FB, and AT declare funded by ISCIII (CIBERESUCICOVID, COV20/00110). EN-L, SS, CC, RQ and BA were funded by Fondecyt 1211480 and COVID-19 Genomics Network (C19-GenoNet) ACT210085. Figure 1 was created with BioRender.com and Flow Cytometer was funded by EQM150061 (FONDEQUIP-ANID). 2022 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion https://doi.org/10.3389/fmed.2022.884218 2296-858X http://hdl.handle.net/10459.1/83668 eng Reproducció del document publicat a: https://doi.org/10.3389/fmed.2022.884218 Frontiers in Medicine, 2022, vol. 9 cc-by (c) Authors 2022 info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/4.0/ Frontiers Media